TELA Bio, Inc. (NASDAQ: TELA) announced its participation in Piper Sandler’s 36th Annual Healthcare Conference, a premier ...
Caitlin Cronin, an analyst from Canaccord Genuity, maintained the Buy rating on TELA Bio (TELA – Research Report). The associated price target remains the same with $12.00. Don't Miss our Black Friday ...
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions ...